Compare Amgen, Inc. (AMGN) vs Ford Motor Company (F) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Ford Motor Company — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Ford Motor Company trades at $13.97 (market cap $55.79B). The key difference: Amgen, Inc. is far larger — about 3.5× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.29%). Which is the better fit depends on your goals.
| AMGN | F | |
|---|---|---|
Market Cap | $196.12B | $55.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $17.44 |
52-Week Low | $271.18 | $10.82 |
Enterprise Value | $241.41B | $184.81B |
Dividend Yield | 2.77% | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Ford (F) trades at $13.995, up 2.83% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent developments include a tentative labor agreement in Canada and JD Power quality recognition, though vehicle recalls and declining EV sales present headwinds.
Ford's valuation appears attractive with low P/E and P/S ratios, but fundamental weakness in profitability and rising debt levels warrant caution. Analyst consensus leans neutral with $14.89 price target, while institutional sentiment shows divided opinions. The stock offers value potential if operational improvements materialize, but execution risks and competitive pressures remain significant concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
